8/23
12:17 pm
sonn
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.
Low
Report
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.
8/23
11:35 am
sonn
Rating for SONN
Low
Report
Rating for SONN